- Cytolon and T-Cell Europe agree on cooperation
- Cytolon initiates global development of DIT - Distributed-Inventory-TechnologyTM
- Cytolon joins Personalized Medicine Coalition
- Cytolon successful with second financing round
- Cytolon gains Patent for CordMatch® in Australia
- Cytolon and DKMS Cord Blood Bank announce collaboration for CordMatch’s Beta-Testing Phase
- Timm Jessen Joins Cytolon’s Supervisory Board
- Cytolon Partners with iSoft for New Life Science Research Tool
- Michaela Servas joins Cytolon´s Supervisory Board
- Cytolon Co-Founder Prof. Dr. Joachim Dudenhausen receives Order of Merit
- CordMatch® goes live
- Cytolon Partners with CSC to Develop CordMatch®
- Cytolon Closes Its First Round of Financing
- Wolfgang Jünger Joins Cytolon's Supervisory Board
- Katherina Reiche, MdB, Steps Down From Cytolon's Supervisory Board to Become a Member of the Federal Government of Germany
- Cytolon Receives the "MOST PROMISING COMPANY LAUNCHED IN 2009 AWARD"
- Cytolon Announces Cooperative Agreement with ARCWAY
- Start-up Financing Begins
- The Launching of Cytolon AG
CordMatch® goes live
Berlin, June 24th 2010 - Cytolon AG announced today going live with the release 1.0 of the CordMatch® platform. After 18 months of market research and hundreds of interviews with health care professionals from transplantation centers (TCs), cord blood banks (CBBs) and involved organizations, a comprehensive set of specifications was created. This was the basis for designing a superior platform. CordMatch® was built by Cytolon´s partner, Computer Science Corporation “CSC”, one of the top leaders in the healthcare information technology field. In these last few months, the CordMatch® platform release 1.0 was tested by selected TCs, CBBs and it is now going live for a beta test in the market during the next nine months.
CordMatch® is unique and the first comprehensive platform designed especially for the matching of cord blood units, particularly for providing solutions for transplantations that require multiple cord blood units. Moreover, the dialog-oriented user interfaces are state-of-the-art and facilitates the processes from search to transplantation, thus decreasing the time and workload needed by health care professionals to find the appropriate match(es) for a patient.
Thomas Klein, founder and CEO of Cytolon AG, stated, “we are thrilled to see such an innovative idea come to completion and become functional.” Furthermore, Klein added, “more patients will now be able to get the best-matched solution in the shortest amount of time” and “we invite CBBs and TCs to participate on this impressive advancement during the ß-testing phase.”
For more information, please consult Cytolon´s website www.cytolon.com or write to cordmatch@cytolon.com.
About Cytolon AG:
Cytolon AG is a private Company based in Berlin, Germany that has developed a proprietary, patent-pending, global, internet-based cord blood brokering platform termed CordMatch®. This platform is positioned to profit from the crossroad of the personal data and cellular therapeutic markets of regenerative medicine. Cytolon's mission is to be the world's first trusted source for getting the correct, best-matched cord blood unit (CBU) to the patient that needs it in a timely manner. An accurate cord blood matching platform is imperative as a CBU must accurately match the histocompatibility antigens and the genetic needs of the patient. Cytolon provides solutions and services for today and the future so world-wide transplant centers can talk efficiently and effectively to world-wide cord blood banks, registries, industry partners and service providers. Cytolon focuses on penetrating immediate and emerging markets in the cord blood and stem cell areas. For more information, please visit the company's Web site at www.cytolon.com.
Contact:
Nina Hofle - PR Manager
Cytolon AG
Am Karlsbad 15
10785 Berlin - Germany
phone: +49 (0) 30 2639 28816
fax: +49 (0) 30 2639 28820
e-mail: info@cytolon.com
web: www.cytolon.com